Oncology

{0}

FDA Approves Generic Version of Cancer Drug Doxil

On February 4, 2013 the U.S. Food and Drug Administration approved the first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection). Doxorubicin hydrochloride liposome injection is currently on the FDA’s drug shortage list. For products on the shortage list, the FDA’s Office of Generic Drugs is using a priority review system to […]

Cardiovascular Drugs, Top U.S. Prescribed Drugs

{0}

FDA Approves Kynamro for Homozygous Familial Hypercholesterolemia

On January 29, 2012 the U.S. Food and Drug Administration approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density […]

Newer Entries »